Publications by authors named "Ge Lou"

Claim this Profile
A
A multicenter, prospective, non-interventional drug intensive monitoring study of olaparib in a large real-world Chinese patient cohort with ovarian cancer (DIM-OC).
Li Wang, Lingling Xie, Qingshui Li, Yang Shen, Huaying Wang, Ge Lou

J Ovarian Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fuzuloparib with or without apatinib as maintenance therapy in newly diagnosed, advanced ovarian cancer (FZOCUS-1): A multicenter, randomized, double-blind, placebo-controlled phase 3 trial.
Lingying Wu, Jing Wang, Qingshui Li, Danbo Wang, Cuiying Zhang, Ge Lou

CA Cancer J Clin· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical characteristics of vulvar basal cell carcinoma: a multi-center, retrospective study in China.
Tingting Yao, Yuqin Huang, Qin Xu, Guzalnur Abuliz, Minhui Zeng, Ge Lou

Int J Gynecol Cancer· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
USP33-mediated stabilization of c-Myc drives glycolytic reprogramming and promotes ovarian cancer progression.
Dejia Chen, Yue Zhao, Xiaobo Zhang, Xiaocheng Shi, Yiming Liu, Ge Lou

Biochim Biophys Acta Gen Subj· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IBI310 plus sintilimab vs. placebo plus sintilimab in recurrent/metastatic cervical cancer: A double-blind, randomized controlled trial.
Huayi Li, Yu Xu, Xiaofei Jiao, Qin Xu, Zikun Peng, Ge Lou

Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Nomogram Based on Fibrinogen-to-Neutrophil Ratio as a Novel Predictor of Lymph Node Metastasis in Patients with Cervical Cancer and Type 2 Diabetes Mellitus.
Hongying Kuang, Dongxia Yang, Ruoyao Lin, Yaling Tang, Yongli Luo, Ge Lou

Cancer Manag Res· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Restoration of Transgelin 2 Expression Reverses Immune Escape in Ovarian Cancer: A Dawn for Immunotherapy.
Zhiqiang Wang, Ge Lou, Mingzhu Yin

MedComm (2020)· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with a mutation.
Wei Huang, Hongxue Meng, Ye Xu, Lan Huang, Ge Lou

Oncol Lett· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of G2/M checkpoint classifier for personalized treatment in uterine corpus endometrial carcinoma.
Yiming Liu, Yusi Wang, Shu Tan, Xiaochen Shi, Jinglin Wen, Ge Lou

Cancer Cell Int· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and prognostic significance of FBXL6 expression in ovarian cancer.
Dianxin Tao, Shenghan Lou, Wei Huang, Kaidi Sun, Jian Li, Ge Lou

Gene· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First evidence of olaparib maintenance therapy in patients with newly diagnosed homologous recombination deficient positive/BRCA wild-type ovarian cancer: real-world multicenter study.
Jing Li, Youguo Chen, Mian He, Xiaoxiang Chen, Hao Wen, Ge Lou

Front Med· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishment and clinical application of a prognostic index for inflammatory status in triple-negative breast cancer patients undergoing neoadjuvant therapy using machine learning.
Hao Sun, Jian Liang, Shuanglong Xue, Xiaoyan Zhang, Mingqiang Ding, Ge Lou

BMC Cancer· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line bevacizumab plus chemotherapy in Chinese patients with stage III/IV epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer: a phase III randomized controlled trial.
Xiaohua Wu, Jihong Liu, Ruifang An, Rutie Yin, Yu Zhang, Ge Lou

J Gynecol Oncol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrative analyses of genes associated with oxidative stress and cellular senescence in triple-negative breast cancer.
Lihua Wu, Hongyan Zheng, Xiaorong Guo, Nan Li, Luyao Qin, Ge Lou

Heliyon· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial.
Xiaohua Wu, Jianqing Zhu, Rutie Yin, Jiaxin Yang, Jihong Liu, Ge Lou

EClinicalMedicine· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial.
Xiaohua Wu, Jihong Liu, Jing Wang, Li Wang, Zhongqiu Lin, Ge Lou

Nat Med· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant nivolumab plus bevacizumab therapy improves the prognosis of triple-negative breast cancer in humanized mouse models.
Hongyan Zheng, Lihua Wu, Jianfeng Chen, Na Na, Ge Lou

Breast Cancer· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.
Huayi Li, Zikun Peng, Jianqing Zhu, Weidong Zhao, Yi Huang, Ge Lou

BMC Med· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
mA methylation-mediated regulation of LncRNA MEG3 suppresses ovarian cancer progression through miR-885-5p and the VASH1 pathway.
Yan Li, Shenghan Lou, Jian Zhang, Shilu Zhao, Ge Lou

J Transl Med· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of zimberelimab (GLS-010) monotherapy in patients with recurrent or metastatic cervical cancer: a multicenter, single-arm, phase II study.
Lingfang Xia, Jing Wang, Chunyan Wang, Qingming Zhang, Jianqing Zhu, Ge Lou

Int J Gynecol Cancer· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Revealing the inhibitory effect of VASH1 on ovarian cancer from multiple perspectives.
Yan Li, Liang Meng, Ge Lou

Cancer Biol Ther· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoxic tumour-derived exosomal miR-1225-5p regulates M2 macrophage polarisation via toll-like receptor 2 to promote ovarian cancer progress.
Shu Tan, Hao Yu, Zhaocong Zhang, Yiming Liu, Ge Lou

Autoimmunity· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of SMURF2 expression enhances RACK1 stability and promotes ovarian cancer progression.
Yanan Pi, Qiushi Feng, Fusheng Sun, Zhiqiang Wang, Yue Zhao, Ge Lou

Cell Death Differ· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bromodomain and extraterminal (BET) proteins: biological functions, diseases, and targeted therapy.
Zhi-Qiang Wang, Zhao-Cong Zhang, Yu-Yang Wu, Ya-Nan Pi, Sheng-Han Lou, Ge Lou

Signal Transduct Target Ther· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Xiangyu Gao, Nong Xu, Ziyu Li, Lin Shen, Ke Ji, Hanmei Lou, Ge Lou

Lancet Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis